ATH 33.3% 0.4¢ alterity therapeutics limited

Ann: Alterity to Present New Data at the AAN 2024 Annual Meeting, page-12

  1. 585 Posts.
    lightbulb Created with Sketch. 5025
    Hi pivade

    Yes, yes, yes.

    I tried to make this point earlier. Note from my previous post (on 21/2/24)...


    Note: This trial is looking at all the key markers that Big Pharma will want to see. These include, but are not limited to:

    1. change in iron content

    2. change in aggregating alpha-Synuclein levels (this is the one I’m particularly waiting to see)

    3. change in Neurofilament Light Chain Levels


    I stated then that 'changes in alpha-Synuclein levels' are the ones I'm wait for ... if we get these, then we are on the money.

    It's that simple. This message is for BIG PHARMA. This is what I want to see, and I would hope it is what BP are looking for also.

    As always, opinion only.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
0.001(33.3%)
Mkt cap ! $21.28M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $5.491K 1.520M

Buyers (Bids)

No. Vol. Price($)
39 50987030 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 126437200 27
View Market Depth
Last trade - 16.10pm 27/08/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.